NCT00457249View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older

PHASE4CompletedINTERVENTIONAL
Enrollment

1,564

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

November 30, 2008

Conditions
PertussisTetanusDiphtheria
Interventions
BIOLOGICAL

ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed

0.5 mL, IM

BIOLOGICAL

DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed

0.5 mL, IM

Trial Locations (19)

20854

Rockville

22003

Annandale

23187

Williamsburg

30322

Atlanta

37920

Knoxville

44260

Mogadore

44308

Akron

45249

Cincinnati

55417

Minneapolis

60610

Chicago

63141

St Louis

70119

New Orleans

84084

West Jordan

84109

Salt Lake City

84121

Salt Lake City

85014

Phoenix

85224

Chandler

90630

Cypress

93405

San Luis Obispo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00457249 - A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older | Biotech Hunter | Biotech Hunter